Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 2/20 | 0.60 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.55 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.51 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439919 | 0.95 | KLK7 (0.61) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL439918 | 0.95 | KLK7 (0.61) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL29460388 | 0.95 | KLK7 (0.61) | KLK7KLK5MAPTFOLH1ITGB3 | |
| SCHEMBL440526 | 0.93 | KLK7 (0.59) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL440527 | 0.93 | KLK7 (0.59) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL15966718 | 0.93 | FOLH1 (0.62) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL9051618 | 0.93 | FOLH1 (0.62) | KLK7KLK5MAPTSIRT2SIRT1 | |
| SCHEMBL15966648 | 0.92 | SIRT2 (0.59) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL19456560 | 0.92 | KLK7 (0.62) | KLK7KLK5MAPTCA1CA2 | |
| SCHEMBL15253875 | 0.92 | KLK7 (0.60) | KLK7KLK5MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458184-B2 | Compositions of TLR7 and/or TLR8 agonists conjugated to lipids | INVIVOGEN (FR) | 2016-10-04 | — | — | US | disclosed |
| US-9295732-B2 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | INVIVOGEN (FR) | 2016-03-29 | — | — | US | disclosed |
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | CAYLA (FR) | 2014-08-28 | — | — | US | disclosed |
| EP-2769738-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | Invivogen (FR) | 2014-08-27 | — | — | EP | disclosed |
| WO-1992012172-A1 | AMIDES OF ANTIBIOTIC GE 2270 FACTORS | GRUPPO LEPETIT S.P.A. (IT) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140242108-A1 | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists | TLR7, TLR8, TLR9 | KLK7 1489/4885KLK5 3060/4885MAPT 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.